Current Report Filing (8-k)
March 09 2017 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 9, 2017
Date of Report (Date of earliest event reported)
AEVI GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item
2.02.
|
Results
of Operations and Financial Condition.
|
On March 9, 2017, Aevi Genomic Medicine,
Inc., a Delaware corporation (the “Company”), issued a press release regarding its financial results for the three
and twelve months ended December 31, 2016. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
|
Item
9.01.
|
Financial
Statements and Exhibits.
|
(d) Exhibits. The following exhibits are furnished herewith:
Exhibit No.
|
Description
|
|
|
99.1
|
Aevi Genomic Medicine, Inc. Press Release dated March 9, 2017
(furnished pursuant to Item 2.02).
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brian D. Piper
|
|
|
|
Name: Brian D. Piper
|
|
|
|
Title: Chief Financial Officer
|
|
Date: March 9, 2017
Exhibit
Index
Exhibit
Number
|
Exhibit
|
|
|
99.1
|
Aevi Genomic Medicine, Inc. Press Release dated March 9, 2017.
|
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Aevi Genomic Medicine Inc (NASDAQ): 0 recent articles
More Aevi Genomic Medicine, Inc. News Articles